Jounce Therapeutics (NASDAQ:JNCE) CFO Kimberlee C. Drapkin sold 5,267 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $25.01, for a total value of $131,727.67. Following the sale, the chief financial officer now directly owns 5,267 shares of the company’s stock, valued at $131,727.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
NASDAQ JNCE traded down $1.23 during trading on Friday, hitting $18.48. 372,089 shares of the company traded hands, compared to its average volume of 340,821. Jounce Therapeutics has a 12 month low of $11.05 and a 12 month high of $29.29. The firm has a market cap of $619.00, a P/E ratio of -31.54 and a beta of 6.33.
Jounce Therapeutics (NASDAQ:JNCE) last posted its earnings results on Thursday, March 8th. The company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.25. The company had revenue of $13.00 million for the quarter, compared to analyst estimates of $14.95 million. Jounce Therapeutics had a negative return on equity of 10.24% and a negative net margin of 22.76%. The business’s revenue was down 36.0% compared to the same quarter last year. During the same period last year, the company earned $0.05 earnings per share. analysts forecast that Jounce Therapeutics will post -1.04 earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. acquired a new stake in Jounce Therapeutics during the third quarter worth about $124,000. Rhumbline Advisers acquired a new stake in Jounce Therapeutics during the fourth quarter worth about $134,000. American International Group Inc. grew its position in Jounce Therapeutics by 132.2% during the third quarter. American International Group Inc. now owns 9,559 shares of the company’s stock worth $149,000 after buying an additional 5,442 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Jounce Therapeutics by 26.4% during the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after purchasing an additional 2,347 shares in the last quarter. Finally, Ark Investment Management LLC boosted its holdings in Jounce Therapeutics by 558.9% during the second quarter. Ark Investment Management LLC now owns 11,932 shares of the company’s stock valued at $167,000 after purchasing an additional 10,121 shares in the last quarter. 90.30% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/07/insider-selling-jounce-therapeutics-inc-jnce-cfo-sells-131727-67-in-stock/2038004.html.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.